Company / Operating Cash Flow
Ginkgo Bioworks Holdings, Inc. Operating Cash Flow History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$171.1M
FY2025
5-year range
-$319.6M / -$171.1M
FY2021-FY2025
Trend
+46.5%
vs FY2024
Sector context
#157 of 214
Health Care
What the data says
At -$171M, Ginkgo Bioworks Holdings, Inc.'s operating cash flow ranks #157 of 214 in the Health Care sector. Operating Cash Flow returned to growth in FY2025 after 2 years of decline, reaching -$171M.
Based on SEC 10-K filings.
-$171M in FY2025.
Improved from -$296M to -$171M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#157 of 214 in Health CareTop 73% of 214This company -$171.1M Sector average $663.6M
▼
-125.8% below sector average
Key checks
Key Insights
- In FY2025, operating cash flow increased 46.5% year-over-year.
- Ranks #157 out of 214 companies in the Health Care sector.
- Peak operating cash flow was recorded in FY2019.
- Lowest operating cash flow in the period was in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -4.79 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$171.1M | +46.5% |
| FY2024 | -$319.6M | -8.2% |
| FY2023 | -$295.5M | -17.2% |
| FY2022 | -$252.2M | +0.6% |
| FY2021 | -$253.8M | -86.9% |
| FY2020 | -$135.8M | -204.1% |
| FY2019 | -$44.7M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026